Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA.

Van Cangh, Paul;De Nayer, Philippe;De Vischer, L;Sauvage, P.;Opsomer, Reinier-Jacques;et.al.
(1996) Urology — Vol. 48, n° 6A Suppl, p. 67-70 (1996)

Files

No attached file found for this publication.

Details

Authors
  • Van Cangh, PaulUCLouvain
    Author
  • De Nayer, PhilippeUCLouvain
    Author
  • De Vischer, L
    Author
  • Sauvage, P.
    Author
  • Tombal, Bertrandorcid-logoUCLouvain
    Author
  • Lorge, FrancisUCLouvain
    Author
  • Wese, François-XavierUCLouvain
    Author
  • Opsomer, Reinier-JacquesUCLouvain
    Author
Show more
Abstract
OBJECTIVES: Improved discrimination between prostate cancer (PC) and benign prostatic hyperplasia (BPH) is clearly needed. Our aim in this study was to evaluate whether the free to total prostate-specific antigen (PSA) ratio would be useful in the gray zone of 1.8-10 ng/mL total PSA range. METHODS: In a consecutive series of 435 clinic patients referred for prostate evaluation, 308 had a total PSA < 10 ng/mL (92 had PC and 216 BPH). Free and total PSA were measured, and the free to total PSA ratio calculated. RESULTS: Total PSA values were significantly different between the two groups. For the 200 patients with a total PSA < 6 ng/mL, no significant difference in total PSA values were seen (P = 0.411), whereas free to total PSA ratios remained statistically different (P < 0.001). Receiver operating characteristic (ROC) curve analysis comparing the performances of total PSA over the ratio of free to total PSA showed a clear advantage for the ratio at all sensitivity levels. CONCLUSIONS: These data demonstrate that in a significant number (n = 308) of prostatic patients in the diagnostic gray zone of 1.8-10 ng/mL total PSA, the routine use of free to total PSA might be advantageous in discriminating between cancer and benign hyperplasia. This advantage remained for total PSA < 4 ng/mL. Further study is warranted to confirm these findings in an unselected population.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Van Cangh, P., De Nayer, P., De Vischer, L., Sauvage, P., Tombal, B., Lorge, F., Wese, F.-X., & Opsomer, R.-J. (1996). Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA. Urology, 48(6A Suppl), 67-70. https://hdl.handle.net/2078.5/136871 (Original work published 1996)